PHILADELPHIA, May 8, 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"
or the "Company"), a clinical-stage biopharmaceutical company
focused on discovering and developing innovative immunotherapies,
today announced that Steven Kelly,
President and Chief Executive Officer, will present at the JMP
Securities Life Sciences Conference on Monday, May 15 at 1:00 pm
EDT in New York.
A live webcast will be available on the Company's Investor
Events webpage and you can also register to view the webcast for
the JMP Securities Life Sciences Conference here. A replay of
webcasts will be archived at the Company's past events section
of the Investor Relations webpage for a limited time following the
event.
About Carisma
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. The first applications of the platform, developed in
collaboration with the University of
Pennsylvania, are autologous chimeric antigen receptor
(CAR)-macrophages for the treatment of solid tumors. Carisma is
headquartered in Philadelphia, PA.
For more information, please visit www.carismatx.com.
Cautionary Note on Forward-Looking
Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Carisma's business,
strategy, future operations, cash runway, the advancement of
Carisma's product candidates and product pipeline, and clinical
development of Carisma's product candidates, including expectations
regarding timing of initiation and results of clinical trials, and
participation by Carisma in future healthcare industry and investor
conferences. The words ""anticipate," "believe," "contemplate,"
"continue," "could," "estimate," "expect," "goals," "intend,"
"may," "might," "outlook," "plan," "project," "potential,"
"predict," "target," "possible," "will," "would," "could,"
"should," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. For a discussion of these risks
and uncertainties, and other important factors, any of which could
cause Carisma's actual results to differ from those contained in
the forward-looking statements, see the "Risk Factors" set forth in
Exhibit 99.3 to Company's Current Report on Form 8-K filed with the
Securities and Exchange Commission on March
8, 2023, as well as discussions of potential risks,
uncertainties, and other important factors in Carisma's most recent
filings with the Securities and Exchange Commission. Any
forward-looking statements that are made in this press release
speak as of the date of this press release. Carisma undertakes no
obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
Investor Contact:
investors@carismatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference-301818665.html
SOURCE Carisma Therapeutics Inc.